Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: A Randomized Controlled Trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
CONTEXT: There is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine hydrobromide, an acetyl cholesterone inhibitor, has pharmacological properties that might benefit patients with CFS. OBJECTIVE: To compare the efficacy and tolerability of galantamine hydrobromide in patients with CFS. DESIGN, SETTING, AND PATIENTS: Randomized, double-blind trial conducted June 1997 through July 1999 at 35 outpatient centers in the United Kingdom (n = 17), United States (n = 14), the Netherlands (n = 2), Sweden (n = 1), and Belgium (n = 1) involving 434 patients with a clinical diagnosis of CFS (modified US Centers for Disease Control and Prevention criteria). INTERVENTIONS: A total of 89 patients were randomly assigned to receive 2.5 mg of galantamine hydrobromide; 86 patients, 5.0 mg; 91 patients, 7.5 mg; and 86 patients, 10 mg (these patients received medicine in the tablet form 3 times per day); a total of 82 patients received matching placebo tablets 3 times per day. MAIN OUTCOME MEASURES: The primary efficacy variable was the global change on the Clinician Global Impression Scale after 4, 8, 12, and 16 weeks of treatment. Secondary outcomes were changes in core symptoms of CFS on the Chalder Fatigue Rating Scale, the Fibromyalgia Impact Questionnaire, and the Pittsburgh Sleep Quality Index; changes in quality of life on the Nottingham Health Profile; and assessment of plasma-free cortisol levels and cognitive performance on a computer-based battery of tests. RESULTS: After 16 weeks, there were no statistically significant differences between any of the galantamine or placebo groups in clinical condition on the Clinician Global Impression Scale, or for any of the secondary end points. Exploratory regression analysis failed to detect any consistent prognostic factor that might have influenced the primary or any secondary outcome measures. CONCLUSION: This trial did not demonstrate any benefit of galantamine over placebo in the treatment of patients with CFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a fatigue scale
Chalder, T., Berelowitz, G., Pawlikowska, T., Watts, L., Wessely, S., Wright, D., & Wallace, E. P. (1993) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(93)90081-p · Cited by 3,032 · cited 5×
“Mean (SD) [range] 39.1 (10.30) [18-57] 38.9 (11.86) [19-64] 39.0 (11.47) [18-60] 37.0 (11.57) [ 18-67 ] 37.6 (9.76) [18-56]”
InfluentialCognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial.
Sharpe, M., Hawton, K., Simkin, S., Surawy, C., Hackmann, A., Klimes, I., Peto, T., Warrell, D., & Seagroatt, V. (1996) · BMJ · doi:10.1136/bmj.312.7022.22 · Cited by 528
Hypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia
Crofford, L. J., Pillemer, S. R., Kalogeras, K. T., Cash, J. M., Michelson, D., Kling, M. A., Sternberg, E. M., Gold, P. W., Chrousos, G. P., & Wilder, R. L. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371105 · Cited by 508
An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS)
White, K. P., & Harth, M. (1996) · Pain · doi:10.1016/0304-3959(95)00213-8 · Cited by 81 · cited 1×
“Furthermore, an analytical review of 24 controlled trials in fibromyalgia advocated the use of the CGI Scale as the most sensitive and appropriate instrument for the assessment of change in this closely related condition.(21) We adopted the CGI Scale as the primary measure of outcome (a score of zero indicated very mu…”
Method
Cited by
Prins, J. B., van der Meer, J. W., & Bleijenberg, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68073-2 · Cited by 974
Smith, M. E. B., Haney, E., McDonagh, M., Pappas, M., Daeges, M., Wasson, N., Fu, R., & Nelson, H. D. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0114 · Cited by 142
“Galantamine was associated with higher rates of withdrawal and attrition than was placebo, demonstrating a dose-dependent relationship; the highest rates were seen at doses of 15 mg or more per day (26).”
BackgroundInfluentialPersonality and chronic fatigue syndrome: methodological and conceptual issues
van Geelen, S. M., Sinnema, G., Hermans, H. J. M., & Kuis, W. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.01.010 · Cited by 52
Kim, D.-Y., Lee, J.-S., & Son, C.-G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113463 · Cited by 24
Metadata
- Authors
- Blacker, C. V. R., Greenwood, D. T., Wesnes, K. A., Wilson, R., Woodward, C., Howe, I., & Ali, T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-09-08
- Volume
- 292
- Issue
- 10
- Pages
- 1195
- ISSN
- 0098-7484
- OpenAlex
- W2096844750
- Cited by
- 44
- References
- 4
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.292.10.1195
- The paper
- Blacker, C. V. R., Greenwood, D. T., Wesnes, K. A., Wilson, R., Woodward, C., Howe, I., & Ali, T. (2004). Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: A Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.292.10.1195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.